{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:38:18Z","timestamp":1787063898843,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T00:00:00Z","timestamp":1526515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004061","name":"Oesterreichische Nationalbank","doi-asserted-by":"publisher","award":["15941"],"award-info":[{"award-number":["15941"]}],"id":[{"id":"10.13039\/501100004061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2018,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Early glucose lowering intervention in subjects with type 2 diabetes mellitus was demonstrated to be beneficial in terms of micro- and macrovascular risk reduction. However, most of currently ongoing cardiovascular outcome trials are performed in subjects with manifest atherosclerosis and long-standing diabetes. Therefore, the aim of this study is to investigate the effects of the dipeptidylpeptidase-4 inhibitor linagliptin in subjects with coronary artery disease (CAD) but early type 2 diabetes mellitus (T2DM) on a set of cardiovascular surrogate measurements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this randomized, placebo-controlled, double-blind, single-center study, we included subjects with early diabetes (postchallenge diabetes (2\u00a0h glucose\u2009&gt;\u2009200\u00a0mg\/dl) or T2DM treated with diet only or on a stable dose of metformin monotherapy and an HbA1c\u2009&lt;\u200975\u00a0mmol\/mol) and established CAD. Participants were randomized to receive either linagliptin (5\u00a0mg) once daily orally or placebo for 12\u00a0weeks. The primary outcome was the change in flow mediated dilatation (FMD). The secondary objective was to investigate the effect of linagliptin treatment on arginine bioavailability ratios [Global arginine bioavailability ratio (GABR) and arginine to ornithine ratio (AOR)]. Arginine, ornithine and citrulline were measured in serum samples with a conventional usual amino acid analysis technique, involving separation of amino acids by ion exchange chromatography followed by postcolumn continuous reaction with ninhydrin. GABR was calculated by\n                      <jats:sc>l<\/jats:sc>\n                      -arginine divided by the sum of (\n                      <jats:sc>l<\/jats:sc>\n                      -ornithine plus\n                      <jats:sc>l<\/jats:sc>\n                      -citrulline). The AOR was calculated by dividing\n                      <jats:sc>l<\/jats:sc>\n                      -arginine by\n                      <jats:sc>l<\/jats:sc>\n                      -ornithine levels. Group comparisons were calculated by using a two-sample t-test with Satterthwaite adjustment for unequal variances.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We investigated 43 patients (21% female) with a mean age of 63.3\u2009\u00b1\u20098.2\u00a0years. FMD at baseline was 3.5\u2009\u00b1\u20093.1% in the linagliptin group vs. 4.0\u2009\u00b1\u20092.9% in the placebo group. The change in mean FMD in the linagliptin group was not significantly different compared to the change in the placebo group (0.43\u2009\u00b1\u20094.84% vs. \u2212\u20090.45\u2009\u00b1\u20093.01%; p\u2009=\u20090.486). No significant improvements were seen in the arginine bioavailability ratios (GABR; p\u2009=\u20090.608 and AOR; p\u2009=\u20090.549).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Linagliptin treatment in subjects with CAD and early T2DM did not improve endothelial function or the arginine bioavailability ratios.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registration<\/jats:italic>\n                      ClinicalTrials.gov, NCT02350478 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02350478\">https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02350478<\/jats:ext-link>\n                      )\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-018-0716-x","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T07:16:15Z","timestamp":1526541375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial"],"prefix":"10.1186","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct02350478","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Norbert J.","family":"Tripolt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Aberer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Riedl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmin","family":"Url","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudrun","family":"Dimsity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Meinitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Stojakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"H\u00f6dl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Brachtl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Strunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Brodmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Hafner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"issue":"7258","key":"716_CR1","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405\u201312.","journal-title":"BMJ"},{"issue":"5","key":"716_CR2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2337\/dc05-2226","volume":"29","author":"H Sourij","year":"2006","unstructured":"Sourij H, Zweiker R, Wascher TC. Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diab Care. 2006;29(5):1039\u201345.","journal-title":"Diab Care"},{"issue":"3","key":"716_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/dom.12591","volume":"18","author":"M Nauck","year":"2016","unstructured":"Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Diab Obes Metab. 2016;18(3):203\u201316.","journal-title":"Diab Obes Metab"},{"issue":"14","key":"716_CR4","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","volume":"369","author":"WB White","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327\u201335.","journal-title":"N Engl J Med"},{"issue":"14","key":"716_CR5","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","volume":"369","author":"BM Scirica","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317\u201326.","journal-title":"N Engl J Med"},{"issue":"3","key":"716_CR6","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1056\/NEJMoa1501352","volume":"373","author":"JB Green","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232\u201342.","journal-title":"N Engl J Med"},{"issue":"3","key":"716_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1177\/1479164115570301","volume":"12","author":"N Marx","year":"2015","unstructured":"Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, et al. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin vs. glimepiride in type 2 diabetes [CAROLINA(R)]. Diab Vasc Dis Res. 2015;12(3):164\u201374.","journal-title":"Diab Vasc Dis Res"},{"issue":"6","key":"716_CR8","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1378\/chest.127.6.2254","volume":"127","author":"AL Moens","year":"2005","unstructured":"Moens AL, Goovaerts I, Claeys MJ, Vrints CJ. Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest. 2005;127(6):2254\u201363.","journal-title":"Chest"},{"key":"716_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12933-016-0414-5","volume":"15","author":"C Manrique","year":"2016","unstructured":"Manrique C, Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Martinez-Lemus LA, Ramirez-Perez FI, Klein T, et al. Dipeptidyl peptidase-4 inhibition with linagliptin prevents western diet-induced vascular abnormalities in female mice. Cardiovasc Diabetol. 2016;15:94.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"716_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12933-018-0704-1","volume":"17","author":"AR Aroor","year":"2018","unstructured":"Aroor AR, Manrique-Acevedo C, DeMarco VG. The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. Cardiovasc Diabetol. 2018;17(1):59.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"716_CR11","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/JME-17-0005","volume":"59","author":"AA Hasan","year":"2017","unstructured":"Hasan AA, Hocher B. Role of soluble and membrane-bound dipeptidyl peptidase-4 in diabetic nephropathy. J Mol Endocrinol. 2017;59(1):R1\u201310.","journal-title":"J Mol Endocrinol"},{"key":"716_CR12","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12933-014-0110-2","volume":"13","author":"K Nakamura","year":"2014","unstructured":"Nakamura K, Oe H, Kihara H, Shimada K, Fukuda S, Watanabe K, Takagi T, Yunoki K, Miyoshi T, Hirata K, et al. DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study. Cardiovasc Diabetol. 2014;13:110.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"716_CR13","doi-asserted-by":"publisher","first-page":"e003277","DOI":"10.1161\/JAHA.112.003277","volume":"2","author":"M Ayaori","year":"2013","unstructured":"Ayaori M, Iwakami N, Uto-Kondo H, Sato H, Sasaki M, Komatsu T, Iizuka M, Takiguchi S, Yakushiji E, Nakaya K, et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013;2(1):e003277.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"716_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12933-016-0493-3","volume":"16","author":"T Jax","year":"2017","unstructured":"Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol. 2017;16(1):13.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"716_CR15","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13063-016-1627-3","volume":"17","author":"NJ Tripolt","year":"2016","unstructured":"Tripolt NJ, Aberer F, Riedl R, Hutz B, Url J, Dimsity G, Meinitzer A, Stojakovic T, Hodl R, Brodmann M, et al. The effects of linagliptin on endothelial function and global arginine bioavailability ratio in coronary artery disease patients with early diabetes: study protocol for a randomized controlled trial. Trials. 2016;17(1):495.","journal-title":"Trials"},{"issue":"3","key":"716_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1537-2995.2005.04056.x","volume":"45","author":"D Strunk","year":"2005","unstructured":"Strunk D, Rohde E, Lanzer G, Linkesch W. Phenotypic characterization and preclinical production of human lineage-negative cells for regenerative stem cell therapy. Transfusion. 2005;45(3):315\u201326.","journal-title":"Transfusion"},{"issue":"2","key":"716_CR17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1182\/blood-2014-04-572255","volume":"125","author":"A Reinisch","year":"2015","unstructured":"Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, Chan CK, Senarath-Yapa K, Seo EY, Wearda T, et al. Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood. 2015;125(2):249\u201360.","journal-title":"Blood"},{"issue":"30","key":"716_CR18","doi-asserted-by":"publisher","first-page":"3245","DOI":"10.2174\/138161211797904127","volume":"17","author":"D Strunk","year":"2011","unstructured":"Strunk D. Endothelial progenitor cells: quod erat demonstrandum? Curr Pharm Des. 2011;17(30):3245\u201351.","journal-title":"Curr Pharm Des"},{"issue":"6","key":"716_CR19","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/wsbm.86","volume":"2","author":"J Seita","year":"2010","unstructured":"Seita J, Weissman IL. Hematopoietic stem cell: self-renewal vs. differentiation. Wiley Interdiscip Rev Syst Biol Med. 2010;2(6):640\u201353.","journal-title":"Wiley Interdiscip Rev Syst Biol Med"},{"key":"716_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.vph.2015.08.011","volume":"79","author":"HM Salim","year":"2016","unstructured":"Salim HM, Fukuda D, Higashikuni Y, Tanaka K, Hirata Y, Yagi S, Soeki T, Shimabukuro M, Sata M. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice. Vascul Pharmacol. 2016;79:16\u201323.","journal-title":"Vascul Pharmacol"},{"issue":"1","key":"716_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12933-016-0438-x","volume":"15","author":"T Maruhashi","year":"2016","unstructured":"Maruhashi T, Higashi Y, Kihara Y, Yamada H, Sata M, Ueda S, Odawara M, Terauchi Y, Dai K, Ohno J, et al. Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study. Cardiovasc Diabetol. 2016;15(1):134.","journal-title":"Cardiovasc Diabetol"},{"issue":"12","key":"716_CR22","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1007\/s00125-016-4083-4","volume":"59","author":"C Ott","year":"2016","unstructured":"Ott C, Kistner I, Keller M, Friedrich S, Willam C, Bramlage P, Schmieder RE. Effects of linagliptin on renal endothelial function in patients with type 2 diabetes: a randomised clinical trial. Diabetologia. 2016;59(12):2579\u201387.","journal-title":"Diabetologia"},{"issue":"3","key":"716_CR23","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/jdi.12587","volume":"8","author":"F Shigiyama","year":"2017","unstructured":"Shigiyama F, Kumashiro N, Miyagi M, Iga R, Kobayashi Y, Kanda E, Uchino H, Hirose T. Linagliptin improves endothelial function in patients with type 2 diabetes: a randomized study of linagliptin effectiveness on endothelial function. J Diab Investig. 2017;8(3):330\u201340.","journal-title":"J Diab Investig"},{"key":"716_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00380-018-1136-2","author":"T Koyama","year":"2018","unstructured":"Koyama T, Tanaka A, Yoshida H, Oyama JI, Toyoda S, Sakuma M, Inoue T, Otsuka Y, Node K. Comparison of the effects of linagliptin and voglibose on endothelial function in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, pilot study (EFFORT). Heart Vessels. 2018. https:\/\/doi.org\/10.1007\/s00380-018-1136-2.","journal-title":"Heart Vessels"},{"issue":"11","key":"716_CR25","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/dom.13041","volume":"19","author":"PH Groop","year":"2017","unstructured":"Groop PH, Cooper ME, Perkovic V, Hocher B, Kanasaki K, Haneda M, Schernthaner G, Sharma K, Stanton RC, Toto R, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diab Obes Metab. 2017;19(11):1610\u20139.","journal-title":"Diab Obes Metab"},{"issue":"10","key":"716_CR26","doi-asserted-by":"publisher","first-page":"e365","DOI":"10.1111\/j.1464-5491.2012.03743.x","volume":"29","author":"NJ Tripolt","year":"2012","unstructured":"Tripolt NJ, Meinitzer A, Eder M, Wascher TC, Pieber TR, Sourij H. Multifactorial risk factor intervention in patients with type 2 diabetes improves arginine bioavailability ratios. Diab Med. 2012;29(10):e365\u20138.","journal-title":"Diab Med"},{"issue":"5","key":"716_CR27","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrneph.2017.30","volume":"13","author":"B Hocher","year":"2017","unstructured":"Hocher B, Adamski J. Metabolomics for clinical use and research in chronic kidney disease. Nat Rev Nephrol. 2017;13(5):269\u201384.","journal-title":"Nat Rev Nephrol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-018-0716-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-018-0716-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:07:05Z","timestamp":1628597225000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-018-0716-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,17]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["716"],"URL":"https:\/\/doi.org\/10.1186\/s12933-018-0716-x","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,17]]},"assertion":[{"value":"27 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"71"}}